GAINESVILLE, Fla. — Aug. 13, 2010 — Quick-Med Technologies, Inc., a life sciences company that is
developing innovative technologies for the healthcare and consumer markets, announced today that it
has signed a development agreement with Biosara Corporation, a medical device company targeting
wound dressings for major medical and healthcare providers, along with the multi-billion dollar
organized sports athlete markets.
Under the terms of the agreement, Quick-Med will develop a unique antimicrobial wound
dressing designed specifically for the organized sports segment of the institutional wound care
market. Quick-Med received an initial payment upon entering into the agreement and will receive
additional payments to fully fund the project for the six months that the development is expected
to take. Biosara also has the option to license exclusive right to use the NIMBUS technology in
professional wound care market in return for specified royalty fees.
“We are excited to begin this collaboration to develop innovative wound care products with
Biosara,” said J. Ladd Greeno, Quick-Med’s CEO. “Our cutting-edge, non-leaching antimicrobial
technology is a huge draw for partners like Biosara. This is another significant milestone for our
NIMBUS wound care technology and further validates its superior performance and unparalleled
safety.”
“We are pleased to be working with Quick-Med on development of a new antimicrobial wound
dressing,” said Ted Pappas, President and CEO of Biosara. “Our market research shows there’s a
large demand for the Active Armor(TM) product line that’s being developed. Our extensive
relationships in the global medical community and the professional sports arena have consistently
expressed the need for next generation antimicrobials and other innovative solutions leading to
lower infection rates, lower wound care costs, and less pain.”
About NIMBUS(R)
Quick-Med’s patented technology, NIMBUS(R), is a cutting-edge antimicrobial technology that
has been custom designed for wound care and other medical applications. NIMBUS(R) received de Novo
FDA clearance in 2009 and has been commercialized in traditional wound care applications.
Additional applications under development include advanced wound dressings, medical adhesives, and
catheters.
About Biosara Corporation
Biosara provides revolutionary new medical products that combine innovative functional need
along with a keen sense of product design in the medical device, sports, and general consumer
arenas. The Biosara product line is extremely creative in nature and includes radical deviations on
long standing medically standard products. The core philosophy of Biosara is different. Products
must be a new species.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative
technologies for the healthcare and consumer markets. In addition to NIMBUS(R), the Company is also
developing Stay Fresh(TM), a textile technology platform that provides exceptional, highly durable,
antimicrobial protection for consumer, industrial and military uses; NimbuDerm(TM); a novel
skin-sanitizer technology that provides comfortable, ongoing protection for 6 or more hours; and
MultiStat(R), a family of patented compounds that have been shown to have significant benefit in
promoting the maintenance, healing and repair of skin and eye tissue. For more information, see:
www.quickmedtech.com.
August 24, 2010
